|
![]() |
|
|
Glyburide: profile and news
Why Aren't Drugs Tested on Pregnant Women? Feb 24, 2006 Diabetes Is Seen as a Rising Risk in Mothers-to-Be Feb 18, 2006 Study Finds More Fractures, Less Bone Density In Premenopausal ... Jan 28, 2006 Mortality Rises as Sulfonylurea Dose Increases Jan 20, 2006 Smarter lifestyles can reduce the risk of getting diabetes Jan 12, 2006 Sulfonylureas for Type 2 Diabetes Drugs Linked to Heart Deaths Jan 17, 2006 Risks of sulfonylurea drugs in the treatment of diabetes mellitus Jan 16, 2006 Potential health risk associated with Chinese medicine Shortclean Nov 21, 2005 Health Canada Warning Consumers Not To Take Chinese Medicine ' ... Nov 17, 2005 Hypoglycemia associated with the use of gatifloxacin. Nov 15, 2005 The Effect Of Tracleer™ On Male Fertility with Primary Pulmonary ... Nov 19, 2005 Endocrinology & Metabolism News, September 2005 Oct 3, 2005 Many meds don't mix with the sun Sep 21, 2005 Bristol/Merck Pargluva Combination Use With Sulfonylurea Not ... Sep 9, 2005 Supplement of the Month - Cinnamon Sep 6, 2005 Endocrinology & Metabolism News, September 2005 Sep 7, 2005 Contributions of Basal and Post-Prandial Hyperglycaemia to Micro ... Aug 12, 2005 FDA Sends Warning Letter to Actelion Over Tracleer Web Page Jul 26, 2005 Warning issued by FDA over "Liqiang 4 Capsules" Jul 10, 2005 FDA Warns Consumers About Liqiang 4 Capsules Jul 13, 2005 SERIOUS WARNING ISSUED BY THE FDA CONCERNING "LIQIANG 4" DUE TO ... Jul 6, 2005 FDA Issues Nationwide Alert for "Liqiang 4" Jul 20, 2005 Avandia: decreased HDL cholesterol levels Jul 17, 2005 FDA CAPSULES Jul 12, 2005 Par Pharmaceutical Reports Second-Quarter Sales and Earnings Jul 28, 2005 Ask the internist: Variety of medications can help with diabetes ... Jul 19, 2005 Dr. Gott: Benefits of Chelation Therapy Exaggerated Jul 16, 2005 Alpharma Receives FDA Approval For Glyburide/Metformin HCL Tablets Jun 30, 2005 Warning issued by FDA over "Liqiang 4 Capsules" Jul 10, 2005 Chinese supplement could endanger diabetics Jul 5, 2005 FDA Issues Nationwide Alert for "Liqiang 4" Due to Potential ... Jul 5, 2005 SERIOUS WARNING ISSUED BY THE FDA CONCERNING "LIQIANG 4" DUE TO ... Jul 6, 2005 FDA Warns of Dangers of Liqiang 4 Dietary Supplement Jul 5, 2005 Chinese Supplement a Risk to Diabetics: FDA Jul 2, 2005 FDA warns consumers about Liqiang 4 capsules Jul 1, 2005 Health Highlights: July 3, 2005 Jul 3, 2005 Around Washington Jul 1, 2005 Type 2 diabetes, Avandia may reduce blood pressure Jun 12, 2005 New Data Show Avandia(R) (Rosiglitazone Maleate) May Reduce Blood ... Jun 11, 2005 Top 10 Things to Know About Diabetes Pills Jul 4, 2005 FDA Warns Against Supplement Jul 1, 2005 PEOPLE'S PHARMACY 100,000 Americans die each year due to medical ... Jun 12, 2005 Other information Indication For treatment and management of Type II diabetes mellitus Pharmacology Glyburide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Glyburide is twice as potent as the related second-generation agent glipizide. Mechanism Of Action Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Drug Category Hypoglycemic Agents; Antiarrhythmic Agents; Sulfonylureas; ATC:A10BB Brand Names/Synonyms Abbenclamide; Adiab; Apo-Glibenclamide; Azuglucon; Bastiverit; Benclamin; Betanase; Betanese 5; CHEMBANK74; Calabren; Cytagon; Daonil; Debtan; Dia-Basan; Diabeta; Diabiphage; Dibelet; Duraglucon; Euclamin; Euglucan; Euglucon; Euglucon 5; Euglykon; G106; G2539; GBN 5; Gen-Glybe; Gewaglucon; Gilemal; Glamide; Glibadone; Gliban; Gliben; Glibenbeta; Glibenclamid Al; Glibenclamid Basics; Glibenclamid Fabra; Glibenclamid Genericon; Glibenclamid Heumann; Glibenclamid Riker M.; Glibenclamid-Cophar; Glibenclamid-Ratiopharm; Glibenclamida [Inn-Spanish]; Glibenclamide; Glibenclamidum [Inn-Latin]; Glibenil; Glibens; Glibesyn; Glibet; Glibetic; Glibil; Gliboral; Glicem; Glidiabet; Glimel; Glimide; Glimidstata; Glisulin; Glitisol; Glubate; Gluben; Gluco-Tablimen; Glucobene; Glucohexal; Glucolon; Glucomid; Glucoremed; Glucoven; Glyben; Glybenclamide; Glybenzcyclamide; Glyburide; Glyburide [Usan]; Glycolande; Glycomin; Glynase; HB 419; HD 419; Hemi-Daonil; Hexaglucon; Humedia; KC-120; Lederglib; Libanil; Lisaglucon; Malix; Maninil; Med-Glionil; Melix; Micronase; Miglucan; Nadib; Neogluconin; Norglicem 5; Normoglucon; Novo-Glyburide; Orabetic; Pira; Praeciglucon; Prestab; Prodiabet; Renabetic; Semi-Daonil; Semi-Euglucon; Sugril; Suraben; Tiabet; UR 606; Yuglucon Dosage Forms Oral tablets Absorption Significant absorption within 1 hour and peak plasma levels are reached within 4 hours Interactions -->Interactions for Glyburide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for loss of control. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving MICRONASE, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia. A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism for this interaction is not known. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known. Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmaco-dynamic effects, makes the clinical significance of this interaction uncertain. Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics. Chemical IUPAC Name 5-chloro-N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxy-benzamide Chemical Formula C23H28ClN3O5S Half Life 10 hours Drug Type Approved Drug # Accession No APRD00233 CAS Registry Number 10238-21-8 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |